Explore baxter.com

This site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative.

Important Safety Information
Renal Care EMEA

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Modern PD

    Modern PD offers patients many choices. Are you ready to voice them?

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx

    Innovative Expanded Hemodialysis (HDx) therapy is the next evolution in hemodialysis treatment.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Explore baxter.com

This site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative.

Important Safety Information

Clinical Effectiveness

HDx therapy delivers meaningful and relevant innovation for dialysis patients.

HDx_2020_planets_clipboard_600x260.jpg

Clinical Effectiveness

HDx therapy addresses pathophysiological responses and clinical outcomes that challenge patients undergoing hemodialysis for treatment of end stage kidney disease.1

Importance of Clinical Effectiveness

A sustained reduction in the level of uremic solutes indicates a reduced degree of uremic toxicity in the blood. Evaluation is made in vivo and is assessed over the course of multiple treatments.
187515_HDx_2020_planets_1600x633.jpg

Primary clinical studies illuminate the benefits of HDx therapy enabled by Theranova

For an even broader set of studies, click here

Cozzolino M et al. Effects of a medium cut-off (Theranova®) dialyzer on haemodialysis patients: a prospective, cross-over study.

HDx therapy showed a statistically significant decrease in the rate of infections. Additionally, this study validated MCO (Theranova) membrane's ability to reduce serum concentration of soluble inflammatory mediators, including cytokines.2

Cantaluppi V et al. Removal of large-middle molecules, inhibition of neutrophil activation and modulation of inflammation-telated endothelial dysfunction during expanded hemodialysis (HDx).

HDx therapy may limit neutrophil activation and endothelial dysfunction, key factors of the increased cardiovascular risk of hemodialysis patients.3

Provide Expanded Hemodialysis. Retain HD Simplicity.

Reference library

Hear from patients, nephrologists, and nurses alike share their experience prescribing HDx.  Be reassured by the pioneering commitment of Baxter to dialysis patients the world over and learn how Theranova dialyzers are made.

HDx Evidence Compendium

On-going research and clinical reporting are an integral part of the HDx journey. Explore the expanding evidence related to HDx enabled by Theranova that nephrologists around the world continue to generate.

HDx_page_600x260.png

HDx Therapy Brochure

Here you can find the HDx therapy brochure with more information about prescribing HDx for your hemodialysis patients.

HDx_page_600x260[1].png

HDx Therapy Specification Sheets

Here you can find the detailed profiles of Theranova dialyzers.

Are you interested in learning how HDx - also known as expanded Hemodialysis - can potentially improve your patients’ clinical outcomes?

Contact Me

Important Safety Information:

Theranova dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.
*Do not use Theranova dialyzers in HDF or HF mode.
For safe and proper use of this device, please refer to Instructions for Use.

CE 2797

About Us
Baxter has been a front-runner in the treatment and management of end-stage kidney disease for over 85 years. Today, our state-of-the-art solutions for both hemodialysis and peritoneal dialysis are transforming global renal care. It’s why you can rely on us to be the type of dedicated partner who understands the challenges you face throughout the continuum of care to meet the individual needs of your patients.
 

Baxter, AK 98, AN69, Artis Physio Plus, BiCart, CWP 800, Evodial, Homechoice, Nephral ST, Novaline, Polyflux, Revaclear, Sharesource, Sharesource Adequest, SoftPac, SelectBag, Theralite and Theranova are trademarks of Baxter International Inc. or its subsidiaries.

©Copyright 2024 Baxter. All rights reserved.

GBU-RC46-200007 v1.0 - November 2020